mdx-1097 mdx-1097 mdx-1097 (also called ist-1097 or kappamab) is a monoclonal antibody therapy being assessed in phase iib clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. it is a chimeric version of the mouse monoclonal antibody k-1-21. mdx-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. mdx-1097monoclonal antibodytype?clinical dataother namesist-1097; kappamabidentifierscas number1793022-75-9 mdx-1097 was originally developed by scientists at immune system therapeutics ltd. in 2015, haemalogix pty ltd acquired the rights to mdx-1097 and are now taking it through late stage clinical testing.